Our top pick for
Building a portfolio
NeoGenomics, Inc is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. NeoGenomics employs 1,700 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$25.19 - USD$61.57|
|50-day moving average||USD$48.1718|
|200-day moving average||USD$48.2845|
|Wall St. target price||USD$63.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.038|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NeoGenomics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1304x. In other words, NeoGenomics shares trade at around 1304x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NeoGenomics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$23.8 million.
The EBITDA is a measure of a NeoGenomics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$444.4 million|
|Gross profit TTM||USD$186.4 million|
|Return on assets TTM||-0.88%|
|Return on equity TTM||0.69%|
|Market capitalisation||USD$5.8 billion|
TTM: trailing 12 months
There are currently 6.4 million NeoGenomics shares held short by investors – that's known as NeoGenomics's "short interest". This figure is 11.9% up from 5.7 million last month.
There are a few different ways that this level of interest in shorting NeoGenomics shares can be evaluated.
NeoGenomics's "short interest ratio" (SIR) is the quantity of NeoGenomics shares currently shorted divided by the average quantity of NeoGenomics shares traded daily (recently around 1.1 million). NeoGenomics's SIR currently stands at 5.64. In other words for every 100,000 NeoGenomics shares traded daily on the market, roughly 5640 shares are currently held short.
However NeoGenomics's short interest can also be evaluated against the total number of NeoGenomics shares, or, against the total number of tradable NeoGenomics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeoGenomics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NeoGenomics shares in existence, roughly 50 shares are currently held short) or 0.0743% of the tradable shares (for every 100,000 tradable NeoGenomics shares, roughly 74 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeoGenomics.
Find out more about how you can short NeoGenomics stock.
We're not expecting NeoGenomics to pay a dividend over the next 12 months.
NeoGenomics's shares were split on a 1:100 basis on 15 April 2003. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.
Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $25.19 up to $61.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 0.6845. This would suggest that NeoGenomics's shares are less volatile than average (for this exchange).
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZIONL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.